Led · Debt Financing · Aug 2025

Founded in 2018 by Sachin Bansal and based in Bengaluru, Navi Technologies offers a range of financial services including digital payments (a top-four UPI app in India), lending through Navi Finserv, insurance, and mutual funds. In the financial year ended March 2026, Navi reported revenue of ₹30.91 billion (~$323.33 million) and a net loss of ₹4.66 billion (~$48.74 million), while stating it reached consolidated profitability in Q4 of fiscal 2026. Its app processed over 947 million UPI transactions valued at ₹483.18 billion (~$5.05 billion) in July, and Navi Finserv holds more than ₹130 billion (~$1.4 billion) in assets under management. The company serves hundreds of millions of users across India and has been preparing for an initial public offering while pursuing external institutional capital.

Led · Equity · Jun 2020

The Small Exchange is a Chicago-based futures exchange and registered Designated Contract Market (DCM) with the CFTC that offers smaller, simpler futures products aimed at retail customers. It uses a proprietary trade matching engine and has launched three products: an Equity Index, a Dollar Index, and a Metals Index. The exchange focuses on reducing fee and connectivity barriers to give individual traders and small trading firms better access to futures markets. As of June 1, 2020, it counted 18 partners, including major trading firms and market-makers. The company has previously raised $20 million from industry backers including co-founders tastytrade, Peak6, then Citadel Securities, and Jump Capital. The new investment will be used to invest in operations and expand offerings, including additional futures products and options. The Small Exchange is building a customer-centric futures exchange that offers proprietary, cash-settled indices sized for a range of investors and a unique individual subscription that reduces exchange and market data fees. The platform is powered by a proprietary matching engine and is designed to be capital efficient, simple to use, and easy to understand for retail investors and other market participants. The company positions itself to bridge the futures product gap for investors of all sizes and to standardize products for ease of use. The Small Exchange is backed by co-founders tastytrade and PEAK6 Investments and has announced industry partnerships with CQG and Eventus. It is seeking registration as a Designated Contract Market (DCM) with the CFTC and plans to launch later this year. Financially, the company announced a $10 million strategic financing from Citadel Securities and Jump Capital to support launch and market development.

Participated · Equity · Jul 2018

Worq operates co-working spaces and focuses on creating a community by handling workplace needs and facilitating connections among entrepreneurs, freelancers and businesses. The company currently hosts over 70 teams and approximately 10,000 members. Led by CEO Stephanie Ping and CFO Andrew Yeow, Worq plans to expand its footprint, opening a new location in Subang Jaya in October 2018 and adding additional sites soon. Financially, Worq raised US$2.5M in the reported funding round to support that expansion. Backers in this round included Bangsawan Consulting and Phillip Capital, alongside existing investors. Existing backers include Cradle Fund, SMG, 500 Startups and some private individuals.

Participated · Series B · Oct 2013

Amaranth Medical is a privately held medical device company that developed the FORTITUDE bioresorbable scaffold, designed to provide the strength of metal stents without leaving a permanent implant. Its lead product line includes a non‑drug‑eluting FORTITUDE scaffold previously evaluated in a 13‑patient study and a planned drug‑eluting FORTITUDE intended for further clinical evaluation. Results from the initial study, presented at TCT, suggested the scaffold maintained mechanical integrity with late lumen loss comparable to bare metal stents. The company announced an equity investment from Boston Scientific to advance an international clinical study, pursue a CE Mark application, and support development of a next‑generation FORTITUDE scaffold with thinner struts. Amaranth planned to begin enrolling a second cohort in 2014 to evaluate the drug‑eluting scaffold. The company is headquartered in Mountain View, California, with research and manufacturing operations in Singapore and at its Silicon Valley headquarters, and is led by CEO Kamal Ramzipoor. Prior investors named include Charter Life Sciences, Bio*One Capital, Philip Private Equity, DCP Management and Venstar Capital. Amaranth Medical is a Mountain View, California-based medical device company that has created a novel technology platform for the development and manufacturing of fully bioresorbable scaffolds. Led by Kamal Ramzipoor, General Manager and Chief Technical Officer, the company has research and manufacturing operations in Singapore and at its Silicon Valley headquarters. Its lead product is FORTITUDE™, a bioresorbable scaffold intended for treating coronary artery disease. The company intends to use the funds to develop the upcoming CE Mark clinical trial of FORTITUDE. Amaranth closed a $20m Series B financing to advance these clinical and development activities. The financing involved both new and existing investors, reflecting continued support for its platform.

Participated · Equity · May 2007

Prolacta Bioscience produces human milk–based products and formulas tailored for premature and critically ill infants in neonatal intensive care. The company operates what the article calls the first and only pharmaceutical-grade manufacturing facility for processing human breast milk. Prolacta recently moved from City of Industry into a 40,300-square-foot LEED Gold headquarters in Duarte. Its core product focus is on human milk–derived nutrition rather than standard infant formulas. The company has an established funding history, having raised $69.1 million across six rounds through December 2016, according to Crunchbase. In the most recent reported filing it secured additional capital via a securities sale. Prolacta Bioscience is the nation's leading provider of human milk-based neonatal nutritional products and operates a pharmaceutical-grade manufacturing facility for donor human milk. Its products are used as part of an exclusive human milk diet for extremely premature infants (500–1,250g at birth) and are clinically proven to improve health outcomes and reduce hospital costs compared with cow milk-based fortifiers or preterm formula. The company is described in the release as already substantially profitable while in the early stages of its growth trajectory. Proceeds from the financing will be used to expand Prolacta's commercial presence in European markets and to support clinical trials of its human milk-based products for additional indications both in and out of the NICU. Prolacta also plans to accelerate a therapeutic development program to evaluate human milk oligosaccharides (HMOs) to treat microbiome-related diseases. The company emphasizes product quality and safety in neonatal nutrition and is headquartered in City of Industry, California. Prolacta is a Monrovia, California-based company that develops human milk-based fortifiers used to feed and treat premature infants. Its products are made from human breast milk and aim to avoid necrotizing enterocolitis associated with cow-based fortifiers. The company announced it closed a Series D round led by Health Evolution Partners. Prolacta did not publicly disclose the round size, but a regulatory filing indicates the equity funding was worth $15.0M. As part of the investment, Health Evolution Partners partners Joshua Saipe and Ned Brown joined Prolacta’s board of directors. Prolacta Bioscience is a Monrovia-based company developing a human milk fortifier made from human milk for use in neonatal intensive care units. On May 23, 2007 the firm announced it raised $12M in a funding round. The financing was led by Alta Partners and included DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, Draper Associates L.P., and other investors. Alison de Bord of Alta Partners joined Prolacta's board in conjunction with the round. The article does not disclose operating metrics, terms of the financing, or specific uses for the proceeds. Coverage focuses on the product and investor participation. Prolacta Bioscience is a Monrovia-based company developing specialty formulations of human milk designed for premature and critically ill infants. The firm raised $5M in a Series B prime financing round. Investors in the round included Arcturus Capital, DFJ Mercury, Philip Capital, Funk Ventures Capital, and the Gideon Hixon Fund. Existing investors DFJ Frontier, Draper Richards, and Draper Associates also participated. The company said the round included several high-profile angel investors. The funding was reported on October 4, 2006.